Prognostic Impact of HER2 Overexpression in Intraductal Papillary Neoplasm of the Bile Duct
Journal of Hepato-Biliary-Pancreatic Sciences · 2025-11 · 32 (11) · 838-846
DOI: 10.1002/jhbp.70000 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, online erschienen am 25.08.2025. Verfasst von Shunsuke Onoe und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Bile Duct Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Carcinoma, Papillary. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: KAKENHI, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
Overexpression of human epidermal growth factor receptor 2 (HER2) is a recognized prognostic marker and therapeutic target in oncology. However, its clinical significance in intraductal papillary neoplasm of the bile duct (IPNB) remains unclear.
Methods
This retrospective study reviewed patients who underwent resection for IPNB between 1998 and 2011. HER2 overexpression was evaluated by immunohistochemistry and semi‐quantitatively categorized into four grades (score 0, 1+, 2+, 3+); the former two and the latter two grades defined HER2‐negative and HER2‐positive groups, respectively.
Results
A total of 184 IPNB cases were analyzed, of which 12 patients (6.5%) were diagnosed with HER2‐positive disease. There were no significant differences between the groups in clinicopathologic characteristics such as tumor location, histologic type, or invasion depth, with the exception of superficial extension, which was significantly more frequent in the HER2‐positive group. The HER2‐positive group demonstrated significantly worse overall survival than the HER2‐negative group (25% vs. 49% at 5 years, p = 0.030). In multivariable analysis, HER2 positivity, age ≥ 70, percutaneous transhepatic biliary drainage, nodal metastasis, and positive margin status were identified as independent prognostic factors.
Conclusion
HER2 overexpression is an independent biologic marker for unfavorable survival, though infrequent in IPNB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Pathology and Clinical Laboratories, Nagoya University Graduate School of Medicine, Nagoya, Japan.
ORCID-Profile: Takashi Mizuno, Junpei Yamaguchi, Ryusei Yamamoto, Toshio Kokuryo
Förderung
- KAKENHI
- Japan Society for the Promotion of Science
Zitieren
APA
Onoe, S., Mizuno, T., Watanabe, N., Kawakatsu, S., Yamaguchi, J., Baba, T., Yamamoto, R., Shimoyama, Y., Kokuryo, T., & Ebata, T. (2025). Prognostic Impact of HER2 Overexpression in Intraductal Papillary Neoplasm of the Bile Duct. Journal of Hepato-Biliary-Pancreatic Sciences, 32(11), 838-846. https://doi.org/10.1002/jhbp.70000
Vancouver
Onoe S, Mizuno T, Watanabe N, Kawakatsu S, Yamaguchi J, Baba T, et al. Prognostic Impact of HER2 Overexpression in Intraductal Papillary Neoplasm of the Bile Duct. Journal of Hepato-Biliary-Pancreatic Sciences. 2025;32(11):838-846. doi:10.1002/jhbp.70000
BibTeX
@article{Onoe2025,
author = {Onoe, Shunsuke and Mizuno, Takashi and Watanabe, Nobuyuki and Kawakatsu, Shoji and Yamaguchi, Junpei and Baba, Taisuke and Yamamoto, Ryusei and Shimoyama, Yoshie and Kokuryo, Toshio and Ebata, Tomoki},
title = {Prognostic Impact of HER2 Overexpression in Intraductal Papillary Neoplasm of the Bile Duct},
journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
year = {2025},
volume = {32},
number = {11},
pages = {838--846},
doi = {10.1002/jhbp.70000}
}
EUVIMED